Gregory Katz, MD
Ophthalmology · Ypsilanti, MINPI 1952364994
Payments from drug & device makers
Across 793 payments — averaging $624.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$97K
- Alcon$85K
- Bausch Health US, LLC$81K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$77K
- Novartis$64K
- Bausch & Lomb Americas Inc.$48K
- plus $43K from 27 others
Across 5 payments — averaging $7155.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- NEW World Medical,inc.$36K
What the payments were for
- Consulting fees$79,23220%
- Speaking & faculty fees$258,53464%
- Travel & lodging$40,56010%
- Food & beverage$22,6046%
- Education$1080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 147 | $97,254 |
| Alcon | 163 | $85,273 |
| Bausch Health US, LLC | 4 | $80,900 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 117 | $77,346 |
| Novartis | 83 | $64,149 |
| Bausch & Lomb Americas Inc. | 77 | $47,580 |
| AbbVie(2 entities) | 66 | $22,774 |
| NEW World Medical,inc. | 45 | $11,525 |
| Sun Pharmaceutical Industries Inc. | 23 | $3,081 |
| Alcon Research LLC | 3 | $2,565 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $1,116 |
| Glaukos Corporation | 15 | $916 |
| Oyster Point Pharma, Inc. | 6 | $136 |
| Astellas Pharma US Inc | 1 | $97 |
| Biotissue Holdings Inc. | 4 | $91 |
| Dompe US, Inc. | 3 | $86 |
| Amgen(2 entities) | 5 | $82 |
| Tarsus Pharmaceuticals, Inc. | 3 | $70 |
| Rayner Intraocular Lenses Limited | 2 | $56 |
| Mallinckrodt Enterprises LLC | 2 | $54 |
| Rxsight Inc | 2 | $48 |
| Tearlab Corp | 1 | $46 |
| Thea Pharma Inc. | 2 | $45 |
| Kala Pharmaceuticals, Inc. | 2 | $41 |
| Sight Sciences, Inc. | 2 | $33 |
| Akorn, Inc. | 1 | $18 |
| Carl Zeiss Meditec USA, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Omeros Corporation | 1 | $17 |
| Ocular Therapeutix, Inc. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Eyepoint US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$160,581
- Rhopressa$134,943
- VYZULTA$120,565
- TRAVATAN Z$53,133
- SIMBRINZA$29,445
- Ahmed Glaucoma Valve$8,663
- Kahook Dual Blade$8,663
- XEN$7,176
- Clearpath$4,696
- Streamline$4,696
- Streamline Surgical System$3,854
- XELPROS$2,513
- TRYPTYR$1,158
- Tecnis 1-piece IOL$967
- Tecnis Multifocal Family of 1-piece IOLS$967
- Tecnis Symfony IOL$967
- ILUX$832
- Systane$570
- NGENUITY$530
- Via360$364
How this compares
$495,492 in reported general payments places this provider in the 95th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 64 | $69,788 |
| RocklatanNetarsudil Mesylat/Latanoprost | 109 | $54,532 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 120 | $42,614 |
| LumiganBimatoprost | 74 | $34,300 |
| Cyclosporine | 52 | $31,235 |
| XiidraLifitegrast | 19 | $26,938 |
| Travoprost | 148 | $24,404 |
| Latanoprost | 878 | $20,372 |
| VyzultaLatanoprostene Bunod | 38 | $17,015 |
| RhopressaNetarsudil Mesylate | 23 | $13,118 |
| Brinzolamide | 52 | $11,564 |
| XalatanLatanoprost | 11 | $10,490 |
| Brimonidine Tartrate | 187 | $10,170 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 41 | $9,805 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $7,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $22,774 | $111,088154 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $97,254 | $67,650132 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $47,580 | $43,95357 claims |
| AlconSimbrinza | $85,273 | $42,614120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Ypsilanti
- Mahdi BashaFraser$2.2M
- Thomas WubbenAnn Arbor$1.2M
- Manjool ShahAnn Arbor$745K
- Scott WesthouseGrand Rapids$525K
- Cagri BesirliAnn Arbor$441K
- David BrownSaint Joseph$432K
- Vinay AakaluAnn Arbor$429K
- Timothy PageBirmingham$324K
- David CookeSaint Joseph$276K
- Leslie GrosingerBloomfield Hills$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.